CD176 antibody

Catalog No. ABIN7882460

The Mouse Monoclonal anti-CD176 antibody (Clone A63-C-A9) (ABIN7882460) specifically detects CD176 in IHC (p). The antibody is reactive with Human samples.

Quick Overview for CD176 antibody (ABIN7882460)

Target: CD176 (Thomsen Friedenreich Antigen (CD176))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This CD176 antibody is un-conjugated

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Grade: Carrier-free

Clone: A63-C-A9

Product Details anti-CD176 Antibody

Purpose: Thomsen-Friedenreich Antigen Antibody / CD176 (azide and preservative free)

Purification: PEG precipitation

Immunogen: Neuraminidase-treated human red blood cells were used as the immunogen for this Thomsen-Friedenreich Antigen antibody.

Isotype: IgM, kappa

Application Details

Application Notes: Optimal dilution of the Thomsen-Friedenreich Antigen antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Preservative: Azide free

Storage: 4 °C,-20 °C

Storage Comment: Store the Thomsen-Friedenreich Antigen antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

Target Details for CD176

Target: CD176 (Thomsen Friedenreich Antigen (CD176))

Alternative Name: Thomsen-Friedenreich Antigen

Background: Recognizes a disaccharide epitope, Gal 1-3GalNAc, of Thomsen-Friedenreich (TF) antigen. It is specific for both anomeric forms of the disaccharide (TF and TF , including related structures on the glycolipid) and shows no cross-reactivity with sialylated glycophorin. The Thomsen-Friedenreich antigen acts as an oncofetal antigen, with low expression in normal adult tissues but increasing to fetal levels of expression in hyperplasia or malignancy. It is considered as a pan-carcinoma marker. This MAb is capable to agglutinate desialylated red blood cells. During metastasis, the ability of malignant cells to form multicellular aggregates via homotypic or heterotypic aggregation and their adhesion to the endothelium are critical. The tumor-associated carbohydrate Thomsen-Friedenreich antigen (Gal-GalNAc) is involved in tumor cell adhesion and tissue invasion. It also causes an immune response, and overexpression of the antigen causes cancer cells to be more sensitive to natural killer cell lysis. The Thomsen-Friedenreich antigen is suppressed in normal healthy cells and represents one of the few chemically well-defined antigens associated with tumor malignancy. The presence of the Thomsen-Friedenreich antigen on the surface of cancer cells may result from a divergence from the normal pathway for O-linked glycosylation in these cells, most likely caused by inappropriate localization of the enzymes involved in synthesis of the disaccharide.